Health Condition 1: L210- Seborrhea capitis
Conditions
Interventions
Intervention1: Group A - Lulican Shampoo: Group A - 36 thrice weekly application
Control Intervention1: Group B - ketoconazole shampoo: Group B - 36 thrice weekly application
Sponsors
Anisha Clinic
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult patients (18-65 yrs) diagnosed with scalp seborrheic dermatitis and candidates for shampoo therapy at the discretion by treating physician 2. Willing to use shampoo thrice a week as advised 3. Willing to avoid oil application for study duration 4. Patients willing to refrain from other forms of treatment including other topical, oral medication for seborrheic dermatitis 5. Patients who are willing to appear for regular follow ups and follow the prescribed treatment regularly 6. Patients who are willing to give consent to participate in the study
Exclusion criteria
Exclusion criteria: 1. Pregnant/ Planning to conceive/ Lactating women 2. Immunocompromised patients on corticosteroids, other immunosuppressive or biologic drugs 3. Patients suffering from infectious, auto-immune, or other disorders affecting skin of scalp. 4. Documented and known history of severe systemic disease, necessitating medical treatment, as assessed by the investigator that might interfere with the conduct of the study or the interpretation of results. 5. Patients known to be allergic to the any of the components of the study medications. 6. Use of any topical medication including OTC products for dandruff within 14 days of enrolment. 7. Patients who are receiving drugs which are known to affect scalp or hair. 8. Patients with known malignancy. 9. Refusal to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Seborrheic Dermatitis Severity Score in both the groups at the end of 4 weeks treatment.Timepoint: Time frame â?? at end 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Evaluation of tolerability and cosmetic acceptability at the end of study 2. Number of participants with any Adverse Event (AE) in both the groups 3. Improvement by PGA in both groups 4. Comparison of mean Scalpdex-23 scores in the both the groupsTimepoint: 1 Time frame â?? 4 weeks 2 Time frame â?? up to 4 weeks 3 Time frame â?? 4 weeks 4 4 weeks compared to baseline | — |
Countries
India
Contacts
Public ContactDr Shrichand G Parasramani
Anisha Clinic
Outcome results
None listed